GEMZAR

This brand name is authorized in United States. It is also authorized in Brazil, Estonia, France, Hong Kong SAR China, Japan, Lithuania, Mexico, Singapore, South Africa, Tunisia.

Active ingredients

The drug GEMZAR contains one active pharmaceutical ingredient (API):

1	Gemcitabine UNII U347PV74IL - GEMCITABINE HYDROCHLORIDE
	Gemcitabine (dFdC), which is a pyrimidine antimetabolite, is metabolised intracellularly by nucleoside kinase to the active diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleosides. The cytotoxic effect of gemcitabine is due to inhibition of DNA synthesis by two mechanisms of action by dFdCDP and dFdCTP.
	Read more about Gemcitabine

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01BC05	Gemcitabine	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01B Antimetabolites → L01BC Pyrimidine analogues
Discover more medicines within L01BC05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	507601301152317, 507601302159315
EE	Ravimiamet	1027550, 1027561
FR	Base de données publique des médicaments	61928914, 67491777
HK	Department of Health Drug Office	41786, 41787
JP	医薬品医療機器総合機構	4224403D1030, 4224403D2037
LT	Valstybinė vaistų kontrolės tarnyba	1003036, 1003037
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	079M97
SG	Health Sciences Authority	09416P, 13229P
TN	Direction de la Pharmacie et du Médicament	5513041H, 5513042H
US	FDA, National Drug Code	0002-7501, 0002-7502
ZA	Health Products Regulatory Authority	29/26/306, 29/26/307